Study 12
ABCSG study results attract worldwide attention at US presentation
June, 2nd 2008The Viennese oncologist Prof. Michael Gnant, MD, President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG) presented spectacular study results to the participants of the globally most important cancer conference in Chicago, USA: He demonstrated that treatment with a bisphosphonate crucially improves young breast cancer patients’ chances to remain permanently healthy after their cancer operation
Before an audience of 20,000, the elite of cancer research from across the globe, Dr. Gnant reported how the bisphosphonate, zoledronate or Zoledronic Acid (ZOL), impacts premenopausal, early breast cancer patients’ health. This program included 1,803 women with hormone receptor-positive breast cancer, stage I or II, who had received three years of treatment post-surgery and were followed up for another two years.
The results are truly impressive:
ZOL reduced the risk of recurrence in women with early-stage
breast cancer receiving hormonal treatment. As compared to exclusively
endocrine therapy, adding ZOL to the treatment plan improved the rate
of recurrence-free survival by 35%.
The patients’ overall prognosis in ABCSG-12 is
excellent. Even without adjuvant chemotherapy, more than 98% of these
breast cancer patients are still alive after 5 years – this is
one of the best results of a clinical trial ever presented.
In addition, a trend towards improved overall survival
was observed in women treated with the bisphosphonate.
Overview »
Description of the study »
Key findings »
Pressrelease »